Current and Emerging Therapies for Follicular Lymphoma: Solving Practice Challenges in Community-Based Interprofessional Care Teams

To participate in this activity, please:

An indolent subtype of non-Hodgkin lymphoma, follicular lymphoma is characterized by eventual relapse of disease and the need for multiple lines of therapy, adding to the significant disease burden experienced by patients. Novel targeted agents in the relapsed/refractory setting have afforded new treatment options, but important clinical challenges exist, including optimal treatment sequencing, therapy evaluation and patient selection, transitions of care requirements, as well as toxicity management.

In this 1-hour, online activity, lymphoma expert Jeremy Abramson, MD, shares his experience navigating these challenges as part of an interprofessional, multidisciplinary care team.

This activity is also available as a podcast: You may listen here

Course Credit:

1 AAPA Category I Hour
1 ACPE Contact Hour
1 AMA PRA Category 1 CreditTM
1 ANCC Contact Hour
1 CA-BRN Contact Hour
1 Pharmacology Hour


Opens: 2023-12-22
Closes: 2024-12-22

Target Audience:

This activity is developed to support hematologist-oncologists, hematology-oncology advanced practice providers, pathologists, and pharmacists who manage patients with follicular lymphoma.

This activity is supported by independent educational grants from Genentech, a member of the Roche Group, and Novartis Pharmaceuticals.


In support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Annenberg Center for Health Sciences at Eisenhower designates this knowledge-based activity for a maximum of 1 hour . Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

The Annenberg Center has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 hour AAPA Category 1 CME credits. Approval is valid until December 22, 2024. PAs should only claim credit commensurate with the extent of their participation.

Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 ANCC contact hour, including 1 pharmacology hour.

Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1 contact hour.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

Additional Content Planners

Chris Elder, PharmD, BCOP (Medical Writer)

Advisory Board: Eisai, Genentech, Mirati, Novartis, Pfizer, Pharmacosmos, Sanofi

Kimberly Tyler, ANP-C, AOCNP (Nurse Reviewer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Jeremy S. Abramson, MD, MMSc

    Director, Lymphoma Program
    Jon and Jo Ann Hagler Chair in Lymphoma
    Massachusetts General Hospital Cancer Center
    Associate Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

Learning Objectives

  • Describe disease burden and unmet clinical needs experienced by patients with follicular lymphoma
  • Review current treatment landscape and updates for newly diagnosed and relapsed/refractory follicular lymphoma
  • Incorporate recent efficacy and safety data for newly approved and emerging therapies for relapsed/refractory follicular lymphoma into treatment planning
  • Develop interprofessional management strategies surrounding complications associated with novel agents including monitoring, toxicity management, and transitions of care

Faculty Disclosures

Jeremy S. Abramson, MD, MMSc

Consultant: AbbVie, Astra-Zeneca, BMS, BeiGene, Epizyme, Genentech, Genmab, Interius, Janssen, Kite Pharma, Lilly, Takeda

Research Support: BMS, Cellectis, Merck, Mustang Bio, Seagen